Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01042977




Registration number
NCT01042977
Ethics application status
Date submitted
5/01/2010
Date registered
6/01/2010
Date last updated
17/02/2014

Titles & IDs
Public title
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Scientific title
A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care
Secondary ID [1] 0 0
D1690C00019
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes Mellitus 0 0
Cardiovascular Disease 0 0
Inadequate Glycaemic Control 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dapagliflozin
Treatment: Drugs - Placebo

Experimental: 1 - dapagliflozin 10 mg tablet

Placebo comparator: 2 - matching placebo tablet


Treatment: Drugs: Dapagliflozin
10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period

Treatment: Drugs: Placebo
matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adjusted Mean Change in HbA1c Levels
Timepoint [1] 0 0
Baseline to Week 24
Primary outcome [2] 0 0
Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Timepoint [2] 0 0
Baseline to Week 24
Secondary outcome [1] 0 0
Adjusted Mean Percent Change in Body Weight
Timepoint [1] 0 0
Baseline to Week 24
Secondary outcome [2] 0 0
Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI =27 kg/m²
Timepoint [2] 0 0
Baseline to Week 24
Secondary outcome [3] 0 0
Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF)
Timepoint [3] 0 0
Baseline to Week 8
Secondary outcome [4] 0 0
Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF)
Timepoint [4] 0 0
Baseline to Week 24
Secondary outcome [5] 0 0
Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg
Timepoint [5] 0 0
Baseline to Week 8

Eligibility
Key inclusion criteria
* Type 2 diabetes mellitus.
* Cardiovascular disease
* Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment
Minimum age
45 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients with type 1 diabetes or diabetes insipidus
* Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
* Any clinically significant illness, which would compromise the patient's safety and their participation in the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2012
Sample size
Target
Accrual to date
Final
964
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Research Site - Blacktown
Recruitment hospital [2] 0 0
Research Site - Broadmeadow
Recruitment hospital [3] 0 0
Research Site - Hornsby
Recruitment hospital [4] 0 0
Research Site - Wollongong
Recruitment hospital [5] 0 0
Research Site - Carina Heights
Recruitment hospital [6] 0 0
Research Site - Kippa-ring
Recruitment hospital [7] 0 0
Research Site - Adelaide
Recruitment hospital [8] 0 0
Research Site - Bedford Park
Recruitment hospital [9] 0 0
Research Site - Keswick
Recruitment hospital [10] 0 0
Research Site - Box Hill
Recruitment hospital [11] 0 0
Research Site - Heidelberg
Recruitment hospital [12] 0 0
Research Site - Herston
Recruitment postcode(s) [1] 0 0
- Blacktown
Recruitment postcode(s) [2] 0 0
- Broadmeadow
Recruitment postcode(s) [3] 0 0
- Hornsby
Recruitment postcode(s) [4] 0 0
- Wollongong
Recruitment postcode(s) [5] 0 0
- Carina Heights
Recruitment postcode(s) [6] 0 0
- Kippa-ring
Recruitment postcode(s) [7] 0 0
- Adelaide
Recruitment postcode(s) [8] 0 0
- Bedford Park
Recruitment postcode(s) [9] 0 0
- Keswick
Recruitment postcode(s) [10] 0 0
- Box Hill
Recruitment postcode(s) [11] 0 0
- Heidelberg
Recruitment postcode(s) [12] 0 0
- Herston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Montana
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
North Dakota
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
Argentina
State/province [22] 0 0
Caba
Country [23] 0 0
Argentina
State/province [23] 0 0
Santa Fe
Country [24] 0 0
Argentina
State/province [24] 0 0
Cordoba
Country [25] 0 0
Argentina
State/province [25] 0 0
Salta
Country [26] 0 0
Austria
State/province [26] 0 0
Wien
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Blagoevgrad
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Pernik
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Pleven
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Russe
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sevlievo
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Sofia
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Stara Zagora
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Varna
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
New Brunswick
Country [37] 0 0
Canada
State/province [37] 0 0
Newfoundland and Labrador
Country [38] 0 0
Canada
State/province [38] 0 0
Nova Scotia
Country [39] 0 0
Canada
State/province [39] 0 0
Ontario
Country [40] 0 0
Canada
State/province [40] 0 0
Quebec
Country [41] 0 0
Chile
State/province [41] 0 0
Region Metropolitana
Country [42] 0 0
Germany
State/province [42] 0 0
Damme
Country [43] 0 0
Germany
State/province [43] 0 0
Dortmund
Country [44] 0 0
Germany
State/province [44] 0 0
Homburg
Country [45] 0 0
Germany
State/province [45] 0 0
Munster
Country [46] 0 0
Germany
State/province [46] 0 0
Wangen
Country [47] 0 0
Hungary
State/province [47] 0 0
Ajka
Country [48] 0 0
Hungary
State/province [48] 0 0
Balatonfured
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Esztergom
Country [51] 0 0
Hungary
State/province [51] 0 0
Gyor
Country [52] 0 0
Hungary
State/province [52] 0 0
Komarom
Country [53] 0 0
Hungary
State/province [53] 0 0
Mosonmagyarovar
Country [54] 0 0
Hungary
State/province [54] 0 0
TAT
Country [55] 0 0
Hungary
State/province [55] 0 0
Veszprem
Country [56] 0 0
Poland
State/province [56] 0 0
Bialystok
Country [57] 0 0
Poland
State/province [57] 0 0
Chrzanow
Country [58] 0 0
Poland
State/province [58] 0 0
Gdansk
Country [59] 0 0
Poland
State/province [59] 0 0
Grodzisk Mazowiecki
Country [60] 0 0
Poland
State/province [60] 0 0
Ilawa
Country [61] 0 0
Poland
State/province [61] 0 0
Kielce
Country [62] 0 0
Poland
State/province [62] 0 0
Krakow
Country [63] 0 0
Poland
State/province [63] 0 0
Leczna
Country [64] 0 0
Poland
State/province [64] 0 0
Leczyca
Country [65] 0 0
Poland
State/province [65] 0 0
Lodz
Country [66] 0 0
Poland
State/province [66] 0 0
Lublin
Country [67] 0 0
Poland
State/province [67] 0 0
Mragowo
Country [68] 0 0
Poland
State/province [68] 0 0
Nowy Sacz
Country [69] 0 0
Poland
State/province [69] 0 0
Plock
Country [70] 0 0
Poland
State/province [70] 0 0
Poznan
Country [71] 0 0
Poland
State/province [71] 0 0
Ruda Slaska
Country [72] 0 0
Poland
State/province [72] 0 0
Skierniewice
Country [73] 0 0
Poland
State/province [73] 0 0
Sopot
Country [74] 0 0
Poland
State/province [74] 0 0
Tarnow
Country [75] 0 0
Poland
State/province [75] 0 0
Torun
Country [76] 0 0
Poland
State/province [76] 0 0
Warszawa
Country [77] 0 0
Poland
State/province [77] 0 0
Wroclaw
Country [78] 0 0
Poland
State/province [78] 0 0
Zabrze
Country [79] 0 0
Poland
State/province [79] 0 0
Zgierz
Country [80] 0 0
Poland
State/province [80] 0 0
Zielona Gora

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease
Trial website
https://clinicaltrials.gov/study/NCT01042977
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Dr. Lawrence A Leiter, MD
Address 0 0
Division of Endocrinology & Metabolism, St Michael's Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01042977